Wednesday, July 8, 2026

pharma · Nicotine use

SWEDISH ORPHAN BIOVITRUM

SWEDISH ORPHAN BIOVITRUM clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

IT HQ
3 Employees
TGA registrant Type
Company details
Status
Public
HQ
IT
Employees
3
Programs
2
Drugs
10
Patents
0
Intelligence · Clinical Programs

SWEDISH ORPHAN BIOVITRUM projects

1 ClinicalTrials.gov programs sponsored by SWEDISH ORPHAN BIOVITRUM.

SWEDISH ORPHAN BIOVITRUM has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. NI-501; emapalumab, NI-501; emapalumab

    Swedish Orphan Biovitrum Pty Ltd

    Macrophage activation syndrome (MAS) in the context of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult onset Still's disease (AOSD). MAS in the context of pediatric and adult Systemic Lupus Erythematosus (SLE).

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does SWEDISH ORPHAN BIOVITRUM have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.